Download PDF
CC BY-NC 4.0 · Arch Plast Surg 2013; 40(04): 380-386
DOI: 10.5999/aps.2013.40.4.380
Original Article

Outcomes of Surgical Management of Xanthelasma Palpebrarum

Hoon Young Lee
Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul, Korea
,
Ung Sik Jin
Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul, Korea
,
Kyung Won Minn
Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul, Korea
,
Young-Oh Park
Ever Plastic Surgery Clinic, Seoul, Korea
› Author Affiliations
› Further Information
   Permissions and Reprints

Background Xanthelasma palpebrarum (XP) is a benign disorder manifesting as yellowish cholesterol-laden plaques on the eyelids. This paper presents the outcomes in patients with XP who have undergone surgical excision as the main modality of treatment.

Methods A retrospective review of patients who received surgery for xanthelasma palpebrarum from March 2007 to March 2011 was conducted. Patients were classified into four grades according to the location and extent of the lesion, with grade I being the mildest and grade IV being the most diffuse. Simple excision was performed in grade I and II lesions, while local flaps and skin grafts were performed in the more advanced grades.

Results Ninety-five cases from March 2007 to March 2011 were included in this study. 66 cases (70%), were treated by simple excision. Twenty-four cases (25%) and 5 cases (5%) were treated by simple excision in combination with or without local flaps and skin grafts. In approximately 1/4 of the patients, orbicularis oris muscle involvement was observed. 4 patients (4.2%) developed scar contracture postoperatively, which required a secondary procedure. Recurrence was reported in 3 patients (3.1%). Otherwise. There were no other reports of major complications or disfigurement.

Conclusions We found that for lesions involving the deep dermis and/or muscle, surgical excision was the most appropriate therapeutic option.

Keywords

Xanthomatosis - Foam cells - Reconstructive surgical procedures - Eyelids

This article was presented at the 69th Congress of the Korean Society of Plastic and Reconstructive Surgeons on November 11-13, 2011 in Seoul, Korea.




Publication History

Received: 07 February 2013

Accepted: 27 May 2013

Article published online:
01 May 2022

© 2013. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Rohrich RJ, Janis JE, Pownell PH. Xanthelasma palpebrarum: a review and current management principles. Plast Reconstr Surg 2002; 110: 1310-1314
    PubMedGoogle Scholar
  • 2 Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 1994; 30: 236-242
    CrossrefPubMedGoogle Scholar
  • 3 Mendelson BC, Masson JK. Xanthelasma: follow-up on results after surgical excision. Plast Reconstr Surg 1976; 58: 535-538
    CrossrefPubMedGoogle Scholar
  • 4 Raulin C, Schoenermark MP, Werner S. et al. Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med 1999; 24: 122-127
    CrossrefPubMedGoogle Scholar
  • 5 Borelli C, Kaudewitz P. Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med 2001; 29: 260-264
    CrossrefPubMedGoogle Scholar
  • 6 Cannon PS, Ajit R, Leatherbarrow B. Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. Clin Exp Dermatol 2010; 35: 845-848
    CrossrefPubMedGoogle Scholar
  • 7 Fusade T. Treatment of xanthelasma palpebrarum by 1064-nm Q-switched Nd:YAG laser: a study of 11 cases. Br J Dermatol 2008; 158: 84-87
    PubMedGoogle Scholar
  • 8 Ozdol S, Sahin S, Tokgozoglu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein (a). Int J Dermatol 2008; 47: 785-789
    CrossrefPubMedGoogle Scholar
  • 9 Mittelviefhaus H, Kreusser C, Bohringer D. et al. The underestimated depth of tissue invasion of xanthelasma: a histological study. Klin Monbl Augenheilkd 2011; 228: 14-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Park EJ, Youn SH, Cho EB. et al. Xanthelasma palpebrarum treatment with a 1,450-nm-diode laser. Dermatol Surg 2011; 37: 791-796
    PubMedGoogle Scholar
  • 11 Hintschich C. Argon laser coagulation of xanthelasmas. Ophthalmologe 1995; 92: 858-861
    PubMedGoogle Scholar
  • 12 Katz TM, Goldberg LH, Friedman PM. Fractional photothermolysis: a new therapeutic modality for xanthelasma. Arch Dermatol 2009; 145: 1091-1094
    CrossrefPubMedGoogle Scholar
  • 13 Karsai S, Schmitt L, Raulin C. Is Q-switched neodymium-doped yttrium aluminium garnet laser an effective approach to treat xanthelasma palpebrarum? Results from a clinical study of 76 cases. Dermatol Surg 2009; 35: 1962-1969
    CrossrefPubMedGoogle Scholar
  • 14 Lieb WE, Klink T, Munnich S. CO2 and erbium YAG laser in eyelid surgery. A comparison. Ophthalmologe 2000; 97: 835-841
    CrossrefPubMedGoogle Scholar
  • 15 Lowry JC, Bartley GB, Garrity JA. The role of second-intention healing in periocular reconstruction. Ophthal Plast Reconstr Surg 1997; 13: 174-188
    CrossrefPubMedGoogle Scholar